Goodrx is trading 10.7% lower at $3.17 after disclosing that its first- and second-quarter 2026 financial statements should no longer be relied upon. - The November 2 disclosure cited understated Pharma Direct revenue, and Goodrx expects to report material weaknesses in internal controls. - Preliminary restated revenue is higher, but the disclosure raises concerns about financial-reporting reliability. - The broad-market moves provided do not explain the company-specific decline.